Abstracts tagged "ANCA associated vasculitis"

Abstract Number: 1088 • ACR Convergence 2022
Longitudinal Pattern of Circulating Complement Activation in ANCA Vasculitis
Eveline Wu¹, Elizabeth McInnis², Sarah Lewis², Mary Collie², Lauren Blazek², Kristin Kennedy², Yichun Hu², Susan Hogan², Candace Henderson², Caroline Poulton², Dhruti Chen², Vimal Derebail², J Charles Jennette³, Ronald Falk² and Donna Bunch², ¹University of North Carolina, Chapel Hill, NC, ²UNC Kidney Center, The University of North Carolina Chapel Hill, Chapel Hill, NC, ³Department of Pathology and Laboratory Medicine, The University of North Carolina Chapel Hill, Chapel Hill, NC
Background/Purpose: Evidence is accumulating that alternative complement pathway activation is important in ANCA vasculitis pathogenesis. Our group was the first to show that complement activation…
Abstract Number: 0434 • ACR Convergence 2022
Sex Based Differences in Cardiovascular Conditions Associated with Anti-neutrophil Cytoplasmic Antibody-Associated Vasculitis: A Retrospective Analysis of the National Inpatient Sample
Krishna bashyal, Nischit Baral, Calvin Ghimire, Shravya Balmuri, Arvind Kunadi and Sandip Karki, McLaren Flint, Grand Blanc, MI
Background/Purpose: Anti-neutrophil cytoplasmic antibody( ANCA)-associated vasculitis, characterized by inflammation of small and medium sized blood vessels includes three main conditions - eosinophilic granulomatosis with polyangiitis,…
Abstract Number: 0451 • ACR Convergence 2022
Incidence and Prevalence of ANCA-associated Vasculitis in Southern Sweden – a 23-year Study
Jens Rathmann¹, Mårten Segelmark², Martin Englund³ and Aladdin Mohammad⁴, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Skane Lan, Sweden, ²Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Lund University, Lund, Sweden, ⁴Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: Epidemiologic studies in ANCA associated vasculitis (AAV) have demonstrated geographical variation between different countries as well as increasing incidence and prevalence during the last…
Abstract Number: 1072 • ACR Convergence 2022
Efficacy and Safety Assessment of a Rituximab Biosimilar in Patients with Granulomatosis with Polyangiitis (GPA)
Adil Vural¹, Komal Mushtaq¹, Chao Zhang¹, Mahmoud Alwakeel¹, Vickie Sayles¹, Kristine Duly², Carol Langford¹ and Rula Hajj-Ali³, ¹Cleveland Clinic, Cleveland, OH, ²Cleveland Clinic, Fairview Park, OH, ³Cleveland Clinic, Hunting Valley, OH
Background/Purpose: A biosimilar is a medication that is highly similar to a biologic agent that is already approved by a regulatory organization. Considering the share…
Abstract Number: 1089 • ACR Convergence 2022
Prognostic Value of Proteinuria Monitoring in Anti-neutrophil Cytoplasmic Antibody-associated Vasculitis
Yeo jin lee¹, Soo Min Ahn², Ji Seon Oh³, Yong Gil Kim², Chang Keun Lee², Bin Yoo² and Seokchan Hong², ¹Asan medical center, Seoul, Republic of Korea, ²Department of Rheumatology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Republic of Korea, Seoul, Republic of Korea, ³Department of Information Medicine, Big Data Research Center, Asan Medical Center, Seoul, Republic of Korea
Background/Purpose: Anti-neutrophil cytoplasmic antibody-associated vasculitis (AAV) is an autoimmune disease that can involve various organs systematically. Kidney involvement, one of the major manifestations of AAV,…
Abstract Number: 0435 • ACR Convergence 2022
Onset of ANCA-associated Vasculitides in Systemic Sclerosis: Phenotype, Management and Outcomes
deborah Eshagh¹, Thomas Quéméneur², Alexandre Karras³, Viviane Queyrel⁴, Jean Francois Augusto⁵, Christian Agard⁶, Vincent Audard⁷, Marion Couderc⁸, PIerre Duffau⁹, Cecile-Audrey Durel¹⁰, Stan Faguer¹¹, Noemie Jourde Chiche¹², Aurelie Lavergne¹³, Christian Lavigne⁵, Nicolas Limal¹, Amélie Servettaz¹⁴, Perrine Smets¹⁵, Alexis Regent¹⁶, Luc Mouthon¹⁶ and Benjamin Terrier¹⁶, ¹APHP, Paris, France, ²Valenciennes Hospital, Valenciennes, France, ³HEGP, Paris, France, ⁴CHU NIce, Nice, France, ⁵CHU Angers, Angers, France, ⁶Internal medicine, Nantes University Hospital, Nantes, France, ⁷CHU Henri Mondor, Creteil, France, ⁸University Hospital, Clermont-Ferrand, France, ⁹CHU Bordeaux, Bordeaux, France, ¹⁰CHU Lyon, Lyon, France, ¹¹CHU Toulouse, Toulouse, France, ¹²APHM, Marseille, France, ¹³CHU Rennes, Rennes, France, ¹⁴CHU Reims, Reims, France, ¹⁵CHU Clermont Ferrand, Clermont-Ferrand, France, ¹⁶National Referral Center for Rare Systemic Autoimmune Diseases, Cochin Hospital, Paris, France
Background/Purpose: Systemic sclerosis (SSc) is a complex autoimmune disease characterized by autoantibody production, skin and visceral fibrosis, and vasculopathy. The onset of ANCA-associated vasculitides (AAV)…
Abstract Number: 0452 • ACR Convergence 2022
Evaluation of the 2022 ACR/EULAR Classification Criteria for ANCA-Associated Vasculitis in a Population-based Cohort from Sweden
Jens Rathmann¹, Mårten Segelmark² and Aladdin Mohammad³, ¹Rheumatology, Department of Clinical Sciences, Lund University, Lund, Skane Lan, Sweden, ²Nephrology, Department of Clinical Sciences, Lund University, Lund, Sweden, ³Rheumatology, Department of Clinical Sciences, Lund University, Lund, Sweden
Background/Purpose: The classification of ANCA- associated vasculitis (AAV) has been an area of controversy for many years. Available classifications and definitions are either overlapping and/or…
Abstract Number: 1073 • ACR Convergence 2022
Analysis of Clinical Outcomes in ANCA-associated Vasculitis Treated with Rituximab: Eighty Years a Single Center Experience in Japan
Soko Kawashima¹, Mitsumasa Kishimoto², Yoshinori Komagata³ and Shinya kaname⁴, ¹Kyorin University, Mitaka Tokyo, Japan, ²Kyorin University School of Medicine, Yokohama, Japan, ³Kyorin University School of Medicine, Tokyo, Japan, ⁴Kyorin University, Tokyo, Japan
Background/Purpose: Contrary to many Western countries, MPO-ANCA-associated vasculitis (MPO-AAV) is dominant in Japan. The therapeutic response to rituximab (RTX) may differ. Therefore, we conducted a…
Abstract Number: 1090 • ACR Convergence 2022
Pulmonary Function Testing (PFT) in Patients with Antineutrophil Cytoplasmic Antibodies (ANCA)-associated Vasculitis (AAV): Correlation with Radiologic Imaging
Johannes Dieterich¹, You-Shan Feng², Juliane Mahrhold¹, Abdallah El Rai³ and Bernhard Hellmich¹, ¹Department of Internal Medicine, Rheumatology and Immunology, Medius Kliniken, University of Tübingen, Kirchheim Teck, Germany, ²Institute for clinical Epidemiology and Biometry, University of Tübingen, Tübingen, Germany, ³Department of Radiology und Nuclear Medicine, Medius Kliniken, University of Tübingen, Nürtingen, Germany
Background/Purpose: Although pulmonary manifestations occur frequently in AAV, empirical evidence of their impact on pulmonary function is scarce. This project analyzed PFT data from a…
Abstract Number: L14 • ACR Convergence 2021
Effect of Avacopan, a Selective C5a Receptor Inhibitor, on Kidney Function in Patients with ANCA-Associated Vasculitis
David Jayne¹, Peter Merkel², Annette Bruchfeld³, Duvuru Geetha⁴, Alexandre Karras⁵, John Niles⁶ and Pirow Bekker⁷, ¹University of Cambridge, Cambridge, United Kingdom, ²University of Pennsylvania, Philadelphia, PA, ³Linköping University, Linköping, Sweden, ⁴Johns Hopkins University, Baltimore, MD, ⁵Hopital Europeen Georges Pompidou, Paris, France, ⁶Massachusetts General Hospital, Boston, MA, ⁷ChemoCentryx, Inc., San Carlos, CA
Background/Purpose: Anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis is a life- or organ-threatening condition in which patients experience severe inflammation of small blood vessels; renal disease is…
Abstract Number: 0420 • ACR Convergence 2021
Development and Validation of a Simulation Model for Maintenance Treatment in ANCA-Associated Vasculitis
Zachary Wallace¹, John Stone², Hyon K. Choi³ and Emily Hyle⁴, ¹Massachusetts General Hospital, Newton, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Boston, MA, ³Massachusetts General Hospital, Lexington, MA, ⁴Infectious Diseases, Department of Medicine, Massachusetts General Hospital, Boston, MA
Background/Purpose: ANCA-associated vasculitis (AAV) care has evolved over the last two decades with several approaches to remission maintenance. However, these approaches have trade-offs regarding the…
Abstract Number: 0437 • ACR Convergence 2021
Factors Associated with Reduced Immunogenicity of the BNT162b2 mRNA COVID-19 Vaccine in Patients with Autoimmune Inflammatory Rheumatic Diseases (AIIRD) Treated with Rituximab
Victoria Furer¹, Tali Eviatar², Devy Zisman³, Hagit Peleg⁴, Daphna Paran⁵, David Levartovsky¹, Ilana Kaufman⁶, Michael Zisapel¹, Ofir Elalouf⁷, Roni Meidan¹, Adi Broyde⁸, Ari Polachek⁹, Jonathan Wollman⁷, Katya Meridor¹⁰, Hila Nochomovitz¹, Adi Silberman¹, Dana Rosenberg¹, Joy Feld¹¹, Amir Haddad¹², Tal Gazitt¹³, Muna Elias³, Nizar Hijaze¹⁴, Fadi Kharouf⁴, Gabi Shefer¹, Orly Sharon¹, Sara Pel¹, Sharon Nevo¹ and Ori Elkayam¹⁵, ¹Tel Aviv Sourasky Medical Center, Tel Aviv, Israel, ²Tel Aviv Sourasky Medical Center, Givataim, Israel, ³Carmel Medical Center, Haifa, Israel, ⁴Hadassah Medical Center, Jerusalem, Israel, ⁵Tel Aviv Sourasky Medical Center-Ichilov Hospital, Even Yehuda, Israel, ⁶Tel Aviv Sourasky Medical Center, Petach Tiqwa, Israel, ⁷Tel Aviv Medical Center, Herzliya, Israel, ⁸Tel Aviv Sourasky Medical Center, KIBBUTZ GIVAT HAIM I, Israel, ⁹Sourasky Medical Center, Petah-Tikva, Israel, ¹⁰Tel Aviv Sourasky Medical Center, Kfar Saba, Israel, ¹¹Carmel and Zvulun Medical Centre, Haifa, Israel, ¹²Carmel Medical Centre, Haifa, Israel, ¹³Carmel Hospital, Haifa, Israel, ¹⁴Carmel medical centre, Tamra, Israel, ¹⁵Tel Aviv Medical Center, Tel Aviv, Israel
Background/Purpose: Rituximab (RTX) has been associated with impaired humoral response to vaccination. This study aim was to identify the predictors for a lack of humoral…
Abstract Number: 0421 • ACR Convergence 2021
Negative vs. Positive Antineutrophil Cytoplasmic Antibody Granulomatosis with Polyangiitis, a Case-control Study
Marta Casal Moura, Samuel D. Falde, Ulrich Specks and Misbah Baqir, Mayo Clinic, Rochester, MN
Background/Purpose: Antineutrophil cytoplasmic antibody (ANCA) negative granulomatosis with polyangiitis (GPA) is a challenging diagnosis. There is paucity of literature regarding the clinical course of ANCA-negative…
Abstract Number: 0525 • ACR Convergence 2021
STEAP3, FZD2 and EGFLAM Are Novel Genetic Risk Loci for Granulomatosis with Polyangitis: A Genome Wide Association Study from UK Biobank
Mehmet Hocaoglu¹, Jamal Mikdashi², Yi-Ju Chen², James Perry² and Charles Hong², ¹University of Maryland Medical Center, Midtown Campus, Baltimore, MD, ²University of Maryland School of Medicine, Baltimore, MD
Background/Purpose: Granulomatosis with Polyangitis (GPA) is a systemic ANCA associated small vessel vasculitis. Prior genetic studies demonstrated a strong association of HLA Class II region…
Abstract Number: 0422 • ACR Convergence 2021
Cancer in Patients with ANCA-associated Vasculitis: Which Came First, the Chicken or the Egg?
Elif Ediboglu¹, Riza Can Kardas², Ertugrul Cagri bolek³, Resit Yildirim⁴, DenizCan Guven⁵, Saadettin Kilickap⁵, Omer Dizdar⁵, Melek Yalcin Mutlu⁶, Ozan Cemal Icacan⁷, Gizem Ayan⁸, Emre Bilgin⁸, Nazife Sule Yasar Bilge⁹, Levent Kilic⁸, Timucin Kasifoglu⁴, Cemal Bes¹⁰, Servet Akar¹¹ and Omer Karadag¹², ¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, İzmir, Turkey, ²Hacettepe University Faculty of Medicine, Department of Internal Medicine, Ankara, Turkey, ³Vasculitis Translational Research Program, NIAMS, NIH, US, Lanham, MD, ⁴Eskisehir Osmangazi University, Department of Internal Medicine, Division of Rheumatology, Eskisehir, Turkey, ⁵Hacettepe University Medical Faculty, Department of Medical Oncology, Ankara, Turkey, ⁶University of Health Sciences, Istanbul, ⁷University of Health Sciences, Istanbul, Turkey, ⁸Hacettepe University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Ankara, Turkey, ⁹Eskisehir Osmangazi University Medical Faculty, Eskisehir, Turkey, ¹⁰Saglik Bilimleri University, Basaksehir Cam and Sakura State Hospital – Istanbul, Turkey, Istanbul, Turkey, ¹¹Izmir Katip Celebi University, Faculty of Medicine, Department of Internal Medicine, Division of Rheumatology, Izmir, Turkey, ¹²Hacettepe University, Division of Rheumatology, Department of Internal Medicine, Faculty of Medicine, Ankara, Turkey
Background/Purpose: Many studies linking vasculitis to the development of malignancy based on chronic inflammation, cytotoxicity, emergence of vasculitis as a paraneoplastic disease. Even previous studies…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].